Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several claims align with provided label excerpts (tinea pedis scope, daily thin-layer application for 2 weeks with margin, topical-only/ophthalmic exclusion, irritation guidance to discontinue, and mechanism via sterol biosynthesis/ergosterol). However, multiple claims are either broader than the labeled indication (e.g., athlete’s foot/yeast/ringworm generally) or include dosing/usage elements not supported by the provided label (e.g., “cream or gel/solution depending on product,” continuing for full course after improvement, specific re-evaluation thresholds, broken skin and near-eye/genital cautions, combination with other antifungals/irritants, and persistence causes). Overall alignment is partial due to unsupported or overgeneralized items relative to the limited label excerpts supplied.
Category Scores
Accurate Statements
Naftifine works by interfering with fungal ergosterol formation.
12.4 Microbiology (mechanism): interferes with sterol biosynthesis via inhibition of squalene 2, 3-epoxidase; decreased sterols especially ergosterol.
Naftifine interferes with fungal ergosterol formation, stopping fungi from making essential cell components.
12.4 Microbiology supports decreased sterols/ergosterol; note label excerpt does not use the phrase “essential cell components.”
By limiting fungal growth, naftifine helps clear the infection.
12.3/12.4 describe inhibiting dermatophyte growth; 14 clinical studies show efficacy for interdigital tinea pedis.
Naftifine HCl is applied to clean, dry affected skin.
Not supported by the provided label excerpts.
Patients should follow the product’s directions or clinician instructions when using naftifine HCl.
Not directly supported; however label provides directions for use. (Label excerpt does not include this exact behavioral instruction.)
A clinician may recommend a different antifungal or testing to confirm the cause if infection persists or recurs.
Not supported by the provided label excerpts.
If irritation with naftifine HCl is strong, worsening, or accompanied by swelling or rash beyond the treated area, treatment should be reassessed.
5.1 states to discontinue if irritation or sensitivity develops. The provided excerpt does not specify “strong/worsening,” “swelling,” “rash beyond the treated area,” or “reassess” language.
Local and mild side effects of naftifine HCl can include irritation, burning, redness, or dryness at the site of application.
6.2 lists burning sensation, erythema/redness, dryness, irritation; 6.1 describes application site reactions.
The active ingredient is naftifine.
Drug name indicates naftifine hydrochloride; label shows active ingredient naftifine hydrochloride (naftifine is the active moiety).
‘Naftifine HCl’ refers to naftifine in the hydrochloride salt form.
Dosage forms/strength and active ingredient are naftifine hydrochloride.
Unsupported Statements
Naftifine HCl is an antifungal medicine used to treat fungal infections of the skin.
General claim not specifically supported by the provided label excerpt (indication excerpt is limited to interdigital tinea pedis caused by specific organisms).
Naftifine HCl is used to treat fungal skin diseases such as athlete’s foot.
The provided label excerpt indicates interdigital tinea pedis; “athlete’s foot” is not explicitly stated in the provided excerpts.
Naftifine HCl is used to treat dermatophyte (ringworm-type) infections.
Provided indication is interdigital tinea pedis due to specific organisms; “ringworm-type” is not explicitly supported by the provided excerpts.
Naftifine HCl is used for some cases of fungal skin infections caused by yeast.
Provided indication excerpt restricts to organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum; yeast is not supported.
Naftifine HCl is typically applied to the affected area as a cream or gel/solution depending on the product.
Provided label excerpts only describe NAFTIN® Gel 2%; do not support other formulations or “depending on the product.”
Naftifine HCl is applied to clean, dry affected skin.
Not present in the provided label excerpts.
Patients often need to continue naftifine HCl for the full course even after symptoms improve.
Label excerpt provides a 2-week application regimen but does not include the specific behavioral guidance about continuing after symptom improvement.
If irritation with naftifine HCl is strong, worsening, or accompanied by swelling or rash beyond the treated area, treatment should be reassessed.
Label excerpt says discontinue if irritation or sensitivity develops; does not specify these additional criteria.
People should be cautious using naftifine HCl on broken skin.
Not present in the provided label excerpts.
People should be cautious using naftifine HCl near the eyes, mouth, or inside the genital area unless the specific product instructions allow it.
Label excerpt states topical use only and not ophthalmic, oral, or intravaginal use, but does not provide this specific caution wording.
Caution is advised with naftifine HCl in pregnancy, breastfeeding, or in treating a child, following product or clinician guidance.
Pregnancy/lactation excerpts address lack of data and caution for lactation; pediatric excerpt establishes ages 12–18 and not established <12. The provided claim is generic and not supported as stated.
Combining naftifine HCl with other antifungals or strong topical irritants without guidance can increase irritation.
No interaction/combination guidance is present in the provided label excerpts.
Using other topical products (especially corticosteroids) with naftifine HCl should be checked with a clinician or pharmacist so the regimen matches the infection type.
Not present in the provided label excerpts.
If symptoms do not improve after the expected treatment period, naftifine HCl use may be ineffective due to wrong diagnosis, resistant fungus, inadequate application, or reinfection.
Not present in the provided label excerpts.
Contradictions
Important Omissions
Specific labeled indication organisms and limitation to interdigital tinea pedis (Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum) rather than general “fungal skin diseases,” “ringworm,” or yeast.
Importance:
High
Exact dosage instructions from the label: apply a thin layer once daily to affected areas plus an approximate 1/2 inch margin of healthy surrounding skin for 2 weeks; topical use only and not for ophthalmic, oral, or intravaginal use.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some statements broaden use to yeast and generalized fungal skin diseases not supported by the provided indication excerpt; several dosing/administration cautions and persistence/combination statements are unsupported by the provided label text. The label-supported instruction to discontinue for irritation/sensitivity is not accurately reflected in the more detailed unsupported criteria.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Overgeneralized indications (including yeast) and multiple unsupported usage/caution details not present in the provided label excerpts.
Suggested Improvement
Constrain indications to interdigital tinea pedis caused by the specific labeled organisms; align administration with the label’s exact once-daily thin-layer regimen for 2 weeks with the stated margin; reflect only label-supported safety guidance (discontinue if irritation/sensitivity develops) and avoid adding unsupported cautions (broken skin, near-eye/genital wording) or combination/persistence explanations unless present in the label.